Russell Investments Group Ltd. Has $206,000 Stock Holdings in Recursion Pharmaceuticals, Inc. $RXRX

Key Points

• Russell Investments Group Ltd. reduced its holdings in Recursion Pharmaceuticals by 80.2%, owning 38,898 shares valued at $206,000 after selling 157,754 shares in the first quarter.
• The company reported a negative EPS of ($0.41), missing the consensus estimate, but had revenue of $19.1 million, exceeding analyst expectations of $15.38 million for the quarter.
• Currently, 89.06% of Recursion Pharmaceuticals' stock is owned by institutional investors and hedge funds, reflecting significant interest in the company.

Russell Investments Group Ltd. cut its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 80.2% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 38,898 shares of the company's stock after selling 157,754 shares during the quarter. Russell Investments Group Ltd.'s holdings in Recursion Pharmaceuticals were worth $206,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of RXRX. GAMMA Investing LLC grew its position in shares of Recursion Pharmaceuticals by 39.0% in the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock valued at $38,000 after purchasing an additional 2,026 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at approximately $54,000. San Luis Wealth Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals in the 1st quarter valued at approximately $54,000. ADG Wealth Management Group LLC acquired a new position in shares of Recursion Pharmaceuticals in the 1st quarter valued at approximately $55,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Recursion Pharmaceuticals in the 1st quarter valued at approximately $57,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently issued reports on RXRX shares. Morgan Stanley started coverage on Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price objective for the company. Needham & Company LLC reaffirmed a "buy" rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, July 8th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $7.25.

Recursion Pharmaceuticals Trading Down 0.9%

NASDAQ:RXRX opened at $4.66 on Wednesday. Recursion Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $12.36. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02. The business has a 50 day moving average price of $5.43 and a two-hundred day moving average price of $5.58. The company has a market cap of $2.02 billion, a P/E ratio of -2.62 and a beta of 0.91.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The company had revenue of $19.10 million during the quarter, compared to analyst estimates of $15.38 million. Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The company's quarterly revenue was up 33.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.40) EPS. As a group, analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In other news, insider Najat Khan sold 36,599 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $5.52, for a total value of $202,026.48. Following the completion of the sale, the insider owned 668,197 shares of the company's stock, valued at approximately $3,688,447.44. This represents a 5.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 8.43% of the company's stock.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.